TRIENTINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIENTINE HYDROCHLORIDE (TRIENTINE HYDROCHLORIDE).
Trientine hydrochloride chelates and promotes the urinary excretion of copper. It forms a stable complex with copper, which is then eliminated via the kidneys, reducing copper accumulation in tissues.
| Metabolism | Trientine is not significantly metabolized; it is primarily excreted unchanged in urine. |
| Excretion | Renal: ~50% (as unchanged drug and metabolites); Biliary/Fecal: ~35%; Minor metabolism; total clearance ~30 L/hr. |
| Half-life | Terminal half-life: 8-10 hours (single dose); 4-6 hours after multiple dosing due to enzyme induction; clinical context: requires thrice daily dosing. |
| Protein binding | ~50-60% bound to albumin and gamma globulins; minor binding to other plasma proteins. |
| Volume of Distribution | Vd: 1.3-1.5 L/kg; suggests extensive distribution into total body water and tissues, including high copper storage sites. |
| Bioavailability | Oral: ~70-80% (variable, 60-90% depending on formulation and food effect); food reduces absorption by ~30%. |
| Onset of Action | Oral: ~1-2 hours (peak plasma concentration); clinical effect (copper excretion) begins within hours, full effect by 1-2 weeks. |
| Duration of Action | Copper chelation effect: 8-12 hours after oral dose; requires TID dosing to maintain continuous copper excretion. |
| Molecular Weight | 219.28 |
250-500 mg orally 4 times daily, 1 hour before or 2 hours after meals and at least 1 hour apart from other medications, food, or milk.
| Dosage form | CAPSULE |
| Renal impairment | No specific dose adjustments recommended. Use with caution in severe renal impairment; monitor for potential accumulation. |
| Liver impairment | No specific dose adjustments recommended based on Child-Pugh score. Use with caution in severe hepatic impairment. |
| Pediatric use | For Wilson disease: 20 mg/kg/day orally, divided into 2-3 doses, not to exceed 1500 mg/day. Administer on empty stomach. |
| Geriatric use | No specific dose adjustments. Start at lower end of dosing range; monitor renal function and for potential adverse effects due to age-related decline in organ function. |
| 1st trimester | Limited human data; animal studies show fetal harm. Use only if clearly needed and benefit justifies potential risk. |
| 2nd trimester | May cause copper deficiency in fetus if used in Wilson's disease; monitor copper levels. Avoid if possible. |
| 3rd trimester | May cause copper deficiency in neonate; avoid near term unless essential. |
Clinical note
Comprehensive clinical and safety monograph for TRIENTINE HYDROCHLORIDE (TRIENTINE HYDROCHLORIDE).
| Placental transfer | Trientine crosses the placenta; limited human data, but animal studies show transfer and fetal effects. |
| Breastfeeding | Trientine is excreted into breast milk in small amounts; potential for copper deficiency in infant. Use with caution, monitor infant copper and zinc levels. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to trientine or any componentRheumatoid arthritis (historical use not indicated)Cystinuria (historical use not indicated)
| Precautions | May cause iron deficiency anemia due to chelation of iron; monitor iron levels., Neurological deterioration may occur initially in some patients with Wilson disease., Monitor for hypersensitivity reactions., Use with caution in patients with renal impairment as drug is renally eliminated. |
| Food/Dietary | Avoid food intake within 1 hour before and 2 hours after dosing. Do not take with milk or dairy products as they may chelate copper and reduce drug absorption. Iron supplements should be separated by at least 2 hours. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Based on limited human data, trientine hydrochloride is not associated with major teratogenic effects. However, since copper deficiency can result from therapy, and copper is essential for fetal development, caution is warranted. The drug should be used during pregnancy only if clearly needed. No specific trimester risks are established; the primary concern is potential copper deficiency leading to fetal harm. |
| Fetal Monitoring | Monitor maternal serum copper and ceruloplasmin levels to avoid copper deficiency. Assess for signs of anemia, leukopenia, or thrombocytopenia due to possible bone marrow suppression. In pregnancy, monitor fetal growth and development via ultrasound. Monitor maternal neurologic and hepatic status as appropriate for Wilson disease. |
| Fertility Effects | Animal studies have not shown impaired fertility. In humans, no specific data on fertility effects are available. Since Wilson disease can affect fertility, treatment with trientine may improve fertility by controlling copper overload. |
| Clinical Pearls | Trientine hydrochloride is a copper-chelating agent used for Wilson disease in patients intolerant to penicillamine. Monitor for iron deficiency anemia; coadministration of iron supplements should be separated by at least 2 hours. Use with caution in renal impairment due to potential nephrotoxicity. Administer on an empty stomach (at least 1 hour before or 2 hours after meals) to maximize absorption. |
| Patient Advice | Take trientine on an empty stomach, at least 1 hour before or 2 hours after meals and at least 1 hour apart from any other drugs, milk, or food. · Do not take iron supplements within 2 hours of trientine; they can reduce its effectiveness. · Swallow capsules whole; do not open or chew. · Report any signs of iron deficiency (fatigue, pale skin) or neurological symptoms (worsening tremors, speech difficulties). · Regular monitoring of serum copper and 24-hour urinary copper is required. |